A Narrative Review of Emerging Therapeutics for COVID-19

Willis, Van C; Arriaga, Yull; Weeraratne, Dilhan; Reyes, F. Leonardi; Jackson, Gretchen Purcell

doi:10.1016/j.mayocpiqo.2020.07.004

Cited by 7 publications

(7 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, these antibodies have the potential to help block entry of the virus into the cells and to facilitate viral clearance. CP has been used in several past outbreaks of other pathogens, and is generally understood to prevent infection and shorten duration and severity of the illness [4,57,58]. However, in the case of COVID-19, evidence of clinical benefit derived from CP has thus far been inconsistent, due to a lack of well controlled studies and the challenges associated with CP such as heterogeneity of plasma, lack of standardized protocols in preparing the antibody titers and how best to administer this plasma [59][60][61].…”

Section: Neutralizing Antibodiesmentioning

confidence: 99%

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics

Chitsike

Duerksen-Hughes

2021

Virol J

View full text Add to dashboard Cite

The COVID-19 pandemic has put healthcare infrastructures and our social and economic lives under unprecedented strain. Effective solutions are needed to end the pandemic while significantly lessening its further impact on mortality and social and economic life. Effective and widely-available vaccines have appropriately long been seen as the best way to end the pandemic. Indeed, the current availability of several effective vaccines are already making a significant progress towards achieving that goal. Nevertheless, concerns have risen due to new SARS-CoV-2 variants that harbor mutations against which current vaccines are less effective. Furthermore, some individuals are unwilling or unable to take the vaccine. As health officials across the globe scramble to vaccinate their populations to reach herd immunity, the challenges noted above indicate that COVID-19 therapeutics are still needed to work alongside the vaccines. Here we describe the impact that neutralizing antibodies have had on those with early or mild COVID-19, and what their approval for early management of COVID-19 means for other viral entry inhibitors that have a similar mechanism of action. Importantly, we also highlight studies that show that therapeutic strategies involving various viral entry inhibitors such as multivalent antibodies, recombinant ACE2 and miniproteins can be effective not only for pre-exposure prophylaxis, but also in protecting against SARS-CoV-2 antigenic drift and future zoonotic sarbecoviruses.

show abstract

Section: Neutralizing Antibodiesmentioning

confidence: 99%

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics

Chitsike

Duerksen-Hughes

2021

Virol J

View full text Add to dashboard Cite

show abstract

“…In all, 6.38% (1845/28,904) of the publications were about the development and repurposing of therapies and vaccines for COVID-19 (eg, [44][45][46][47]). The following authors published the highest number of articles related to this topic: Wei Zhang (n=13), Xiuna Yang (n=9), Haitao Yang (n=9), Zihe Rao (n=9), and Yao Zhao (n=8).…”

Section: Topic 5: Therapies and Vaccines For Covid-19mentioning

confidence: 99%

A Comprehensive Overview of the COVID-19 Literature: Machine Learning–Based Bibliometric Analysis (Preprint)

Abd‐Alrazaq¹,

Schneider²,

Mifsud³

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND Shortly after the emergence of the novel coronavirus disease (COVID-19), researchers rapidly mobilized to study numerous aspects of the disease such as its evolution, clinical manifestations, effects, treatments, and vaccination. This led to a rapid increase in the number of COVID-19-related publications. Identifying trends and areas of interest using traditional review methods (e.g, scoping review and systematic reviews) for such a large domain area is challenging. OBJECTIVE We aimed to conduct an extensive bibliometric analysis to provide a comprehensive overview of the COVID-19 literature. METHODS We used the COVID-19 Open Research Dataset (CORD-19) that consists of enormous number of articles related to all coronaviruses. We used machine learning method to analyse most relevant COVID-19 related articles and extracted most prominent topics. Specifically, we used clustering algorithm to group articles based on similarity of their abstracts to identify the research hotspots and current research directions. RESULTS Of the 196,630 publications retrieved from the database, we included 28,904 in the analysis. The mean number of weekly publications was 990 (SD=789.3). The country that published the highest number of articles was China (n=2,950). The largest number of documents was published in BioRxiv. Lei Liu affiliated in the Southern University of Science and Technology in China published the highest number of documents (n=46). Based on titles and abstracts alone, we were able to identify 1,515 surveys, 733 systematic reviews, 512 cohort studies, 480 meta-analyses, 362 randomized control trials. We identified 19 different topics addressed by the included studies. The most dominant topic was public health response followed by clinical care practices during COVID-19, its clinical characteristics and risk factors, and epidemic models for its spread. CONCLUSIONS We provided an overview of the COVID-19 literature and identified current hotspots and research directions. Our findings can be helpful to the research community by helping prioritize research needs, and recognize leading COVID-19 researchers, institutes, countries, and publishers. This study showed that an AI-based bibliometric analysis has the potential to rapidly explore large corpora of academic publications during a public health crisis. Publishers should avoid noise in the data by developing a way to trace the evolution of individual publications and unique authors.

show abstract

“…Much hope for life after the COVID-19 pandemic lies in the potential success of vaccines. Multiple vaccines are in various stages of development, 1 and preliminary results from various trials are promising. [2][3][4] However, the success of a vaccine is incumbent upon uptake in the general population.…”

Section: Introductionmentioning

confidence: 99%

Vaccination in the Philippines: experiences from history and lessons for the future

Reyes

Dee

Ho³

2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In anticipation of a potential vaccine for COVID-19, vaccine uptake may be critical in overcoming the pandemic, especially in countries like the Philippines, which has among the highest rates of infection in the region. Looking at the progress of vaccination in the country -its promises, pitfalls, and challengesmay provide insight for public health professionals and the public. The history of vaccination in the Philippines is marked by strong achievements, such as the establishment and growth of a national programme for immunization, and importantly, the eradication of poliomyelitis and maternal and neonatal tetanus. It is also marred by critical challenges which provide a springboard for improvement across all sectors -vaccine stock-outs, strong opposition from certain advocacy groups, and the widely publicized Dengvaxia controversy. Moving forward, with recent surveys having shown that vaccine confidence has begun to improve, these experiences may inform the approaches taken to address vaccine uptake. These lessons from the past highlight the importance of a strong partnership between health leaders and the local community, bearing in mind cultural appropriateness and humility; the engagement of multidisciplinary stakeholders; and the importance of foresight in preparing public health infrastructure for the arrival of a COVID-19 vaccine.

show abstract

A Narrative Review of Emerging Therapeutics for COVID-19

Cited by 7 publications

References 114 publications

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics

A Comprehensive Overview of the COVID-19 Literature: Machine Learning–Based Bibliometric Analysis (Preprint)

Vaccination in the Philippines: experiences from history and lessons for the future

Contact Info

Product

Resources

About